NAS
NTLA icon

Nykredit A/S’s Intellia Therapeutics NTLA Stock Holding History

Nykredit A/S’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.8K Buy
+1,940
New +$27.2K ﹤0.01% 1590

Other funds holding NTLA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Nykredit A/S's NTLA Position: Q2 2026 in Review

Nykredit A/S opened a new position in Intellia Therapeutics (NTLA) in Q2 2026: 1,940 shares worth $32.8K. The stake represents ﹤0.01% of the portfolio and ranks #1590 among its holdings.

231 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Nykredit A/S held 1,940 shares of Intellia Therapeutics worth $32.8K as of Q2 2026.
  • Intellia Therapeutics was a new Nykredit A/S position in Q2 2026.
  • Intellia Therapeutics made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #1590 holding.
  • 231 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.